[A sero-epidemiologiecal study on hepatitis B among general population in Beijing].
OBJECTIVE
To explore the serological infection rate of hepatitis B virus (HBV) in general population aged over one year old in Beijing and to provide information for control and prevention of the disease.


METHODS
A multistage randomized cluster sampling was carried out in general population of Beijing, aged over one year old. Every study subject's hepatitis B immunization history and main risk factors were investigated through questionnaire. Venous blood samples were collected and then tested for five hepatitis B serological antigens and antibodies by means of Abbott Microparticle Enzyme Immunoassy method.


RESULTS
The prevalence rates of HBsAg, anti-HBs, anti-HBc and total HBV infection rate were 3.49% (95% CI:2.99-3.99), 37.79% (95% CI: 36.46-39.12), 35.04% (95% CI: 33.72-36.35) and 35.09% (33.78-36.40) respectively. The age standardized rates were 3.02% ,42.47% ,26.86% and 26.90% respectively.


CONCLUSIONS
Achievement in hepatitis B control and prevention was made in Beijing since the prevalence rate of hepatitis B surface antigen had been below 1% for children aged less than 5 years old. As for the general population, the prevalence rate of hepatitis B surface antigen had reduced to
Wu
Jiang
J
Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Zhang
Wei
W
Han
Li-li
LL
Lin
Chang-ying
CY
Lin
Hui
H
Xing
Yu-lan
YL
Gao
Pei
P
Gong
Xiao-hong
XH
Liu
Li-rong
LR
Huang
Fang
F
Liu
Jian-ying
JY
Liu
Li-ying
LY
Wang
Hua-yong
HY
Yu
Hai-zhu
HZ
Liu
Xiu-jun
XJ
Tang
Ya-qing
YQ
Pu
Yong-lan
YL
Zhao
Wei
W
Wang
Chen
C
Zhang
Zhen
Z
Ma
Li-xian
LX
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D006509:Hepatitis B / Q000097:blood* / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008875:Middle Aged; D055815:Young Adult
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines